Companies:
49,811
Total Market Cap:
139340529547148.31
Global Rank
#8880
Country Rank
#39
Market Cap
1.15 B
Price
70.56
Change (%)
2.09%
Volume
25,741
Gubra A/S's latest marketcap:
1.15 B
As of 07/05/2025, Gubra A/S's market capitalization has reached $1.15 B. According to our data, Gubra A/S is the 8880th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.15 B |
| Revenue (ttm) | 41.8 M |
| Net Income (ttm) | -5,741,135.4 |
| Shares Out | 16.31 M |
| EPS (ttm) | -0.35 |
| Forward PE | 15.32 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/21/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Gubra A/S's yearly market capitalization.
Gubra A/S has seen its market value drop from kr2.04 B to kr1.15 B since 2023, representing a total decrease of 43.49% and an annual compound decline rate (CAGR) of 31.35%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | kr1.15 B | -29.3% | 8880 |
| 12/30/2024 | kr10.18 B | 399.74% | 7138 |
| 12/29/2023 | kr2.04 B | 16438 |
Company Profile
About Gubra A/S
Gubra A/S is a biotechnology company specializing in pre-clinical contract research and peptide-based drug discovery, with a focus on metabolic and fibrotic diseases. The company operates across Europe, North America, and internationally.
Business Segments
- Pre-Clinical Contract Research (CRO): Provides research and development services for pharmaceutical and biotech industries.
- Discovery & Partnerships: Engages in drug discovery and strategic collaborations.
- Gubra Green: Focuses on sustainable and innovative biotech solutions.
Services Offered
- In vivo pharmacology
- Biomarker assays and bioinformatics
- Next-gen sequencing
- Pharmacokinetics
- 2D and 3D histology with AI pathology
Key Partnerships
- Boehringer Ingelheim: Collaboration for obesity treatments.
- Hemab ApS: Partnership to address bleeding disorders.
- Amylyx Pharmaceuticals, Inc.: Development of a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and rare diseases.
Founded: 2008 | Headquarters: Horsholm, Denmark
Frequently Asked Questions
-
What is Gubra A/S's (CPH-GUBRA) current market cap?As of 07/05/2025, Gubra A/S (including the parent company, if applicable) has an estimated market capitalization of $1.15 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Gubra A/S (CPH-GUBRA) rank globally by market cap?Gubra A/S global market capitalization ranking is approximately 8880 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.